Page 648 - Clinical Immunology_ Principles and Practice ( PDFDrive )

CHaPter 44 Atopic and Contact Dermatitis 623

Please check your eBook at https://expertconsult.inkling.com/ 21. Frisch S, Siegfried EC. The clinical spectrum and therapeutic challenge of
for self-assessment questions. See inside cover for registration eczema herpeticum. Pediatr Dermatol 2011;28:46–52.
details. 22. Noda S, Krueger JG, Guttman-Yassky E. The translational revolution and
use of biologics in patients with inflammatory skin diseases. J Allergy
Clin Immunol 2015;135:324–36.
REFERENCES 22a. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of
dupilumab versus placebo in atopic dermatitis. N Engl J Med
1. Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic 2016;375:2335–48.
dermatitis: shifting paradigms in treatment approaches. J Allergy Clin 23. Boguniewicz M, Nicol N, Kelsay K, et al. A multidisciplinary approach to
Immunol 2014;134:769–79. evaluation and treatment of atopic dermatitis. Semin Cutan Med Surg
2. Boguniewicz M, Leung DY. Recent insights into atopic dermatitis and 2008;27:115–27.
implications for management of infectious complications. J Allergy Clin 24. Roekevisch E, Spuls PI, Kuester D, et al. Efficacy and safety of systemic
Immunol 2010;125:4–13. treatments for moderate-to-severe atopic dermatitis: a systematic review.
3. Odhiambo JA, Williams HC, Clayton TO, et al. Global variations in J Allergy Clin Immunol 2014;133:429–38.
prevalence of eczema symptoms in children from ISAAC Phase Three. 25. Tam HH, Calderon MA, Manikam L, et al. Specific allergen
J Allergy Clin Immunol 2009;124:1251–8.e23. immunotherapy for the treatment of atopic eczema: a systematic review.
4. Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with Allergy 2016;71:1345–56.
asthma and other health and demographic factors: a US population-based 26. Beck LA, Thaci D, Hamilton JD, et al. Dupilumab treatment in adults
study. J Allergy Clin Immunol 2013;132:1132–8. with moderate-to-severe atopic dermatitis. N Engl J Med 2014;371:
5. Margolis JS, Abuabara K, Bilker W, et al. Persistence of mild to moderate 130–9.
atopic dermatitis. JAMA Dermatol 2014;150:593–600. 27. Thaci D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in
6. Ewald DA, Malajian D, Krueger JG, et al. Meta-analysis derived atopic adults with moderate-to-severe atopic dermatitis inadequately controlled
dermatitis (MADAD) transcriptome defines a robust AD signature by topical treatments: a randomised, placebo-controlled, dose-ranging
highlighting the involvement of atherosclerosis and lipid metabolism phase 2b trial. Lancet 2016;387:40–52.
pathways. BMC Med Genomics 2015;8:60. 28. Boguniewicz M, Leung DY. Targeted therapy for allergic diseases: at the
7. Schmitt J, Schwarz K, Baurecht H, et al. Atopic dermatitis is associated intersection of cutting-edge science and clinical practice. J Allergy Clin
with an increased risk for rheumatoid arthritis and inflammatory bowel Immunol 2015;135:354–6.
disease, and a decreased risk for type 1 diabetes. J Allergy Clin Immunol 29. Samrao A, Berry TM, Goreshi R, et al. A pilot study of an oral
2016;137:130–6. phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults.
8. Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with Arch Dermatol 2012;148:890–7.
skin and allergic diseases. N Engl J Med 2011;365:1315–27. 30. Jarnagin K, Chanda S, Coronado D, et al. Crisaborole topical ointment,
9. Tamari M, Hirota T. Genome-wide association studies of atopic 2%: a nonsteroidal, topical, anti-inflammatory phosphodiesterase 4
dermatitis. J Dermatol 2014;41:213–20. inhibitor in clinical development for the treatment of atopic dermatitis. J
10. Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered Drugs Dermatol 2016;15:390–6.
skin barrier and immune dysregulation. Immunol Rev 2011;242: 31. Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of
233–46. the skin barrier from birth offers effective atopic dermatitis prevention. J
11. Kim J, Kim BE, Lee J, et al. Epidermal thymic stromal lymphopoietin Allergy Clin Immunol 2014;134:818–23.
predicts the development of atopic dermatitis during infancy. J Allergy 32. Horimukai K, Morita K, Narita M, et al. Application of moisturizer to
Clin Immunol 2016;137:1282–5.e4. neonates prevents development of atopic dermatitis. J Allergy Clin
12. Cabanillas B, Novak N. Atopic dermatitis and filaggrin. Curr Opin Immunol 2014;134:824–30.e6.
Immunol 2016;42:1–8. 33. Kelleher M, Dunn-Galvin A, Hourihane JO, et al. Skin barrier dysfunction
13. Schneider L, Tilles S, Lio P, et al. Atopic dermatitis: a practice parameter measured by transepidermal water loss at 2 days and 2 months predates
update 2012. J Allergy Clin Immunol 2013;131:295–9.e1–27. and predicts atopic dermatitis at 1 year. J Allergy Clin Immunol
14. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the 2015;135:930–5.e1.
management of atopic dermatitis: section 2. Management and treatment 34. Heine G, Schnuch A, Uter W, et al. Frequency of contact allergy in
of atopic dermatitis with topical therapies. J Am Acad Dermatol German children and adolescents patch tested between 1995 and 2002:
2014;71:116–32. results from the Information Network of Departments of Dermatology
15. Boguniewicz M, Leung DY. The ABC’s of managing patients and the German Contact Dermatitis Research Group. Contact Dermatitis
with severe atopic dermatitis. J Allergy Clin Immunol 2013;132: 2004;51:111–17.
511–2.e5. 35. The Lewin Group, Inc. The burden of skin diseases; 2004. Available at:
16. Bergmann MM, Caubet JC, Boguniewicz M, et al. Evaluation of food www.sidnet.org/files/Burden%20of%20Skin%20Diseases%202004%20
allergy in patients with atopic dermatitis. J Allergy Clin Immunol Pract Final%20Sept%2005. [Accessed 27 May 2014].
2013;1:22–8. 36. Mailhol C, Lauwers-Cances V, Rance F, et al. Prevalence and risk factors
17. Bianchi P, Theunis J, Casas C, et al. Effects of a new emollient-based for allergic contact dermatitis to topical treatment in atopic dermatitis: a
treatment on skin microflora balance and barrier function in children study in 641 children. Allergy 2009;64:801–6.
with mild atopic dermatitis. Pediatr Dermatol 2016;33:165–71. 37. Aquino M, Fonacier L. The role of contact dermatitis in patients with
18. Suarez-Farinas M, Tintle SJ, Shemer A, et al. Nonlesional atopic atopic dermatitis. J Allergy Clin Immunol Pract 2014;2:382–7.
dermatitis skin is characterized by broad terminal differentiation defects 38. Novak N, Baurecht H, Schafer T, et al. Loss-of-function mutations in the
and variable immune abnormalities. J Allergy Clin Immunol filaggrin gene and allergic contact sensitization to nickel. J Invest
2011;127:954–64.e1–4. Dermatol 2008;128:1430–5.
19. Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the 39. Ross-Hansen K, Menne T, Johansen JD, et al. Nickel reactivity and
management of atopic dermatitis: section 3. Management and treatment filaggrin null mutations—evaluation of the filaggrin bypass theory in a
with phototherapy and systemic agents. J Am Acad Dermatol general population. Contact Dermatitis 2011;64:24–31.
2014;71:327–49. 40. Gittler JK, Krueger JG, Guttman-Yassky E. Atopic dermatitis results in
20. Broeders JA, Ahmed Ali U, Fischer G. Systematic review and intrinsic barrier and immune abnormalities: implications for contact
meta-analysis of randomized clinical trials (RCTs) comparing topical dermatitis. J Allergy Clin Immunol 2013;131:300–13.
calcineurin inhibitors with topical corticosteroids for atopic dermatitis: a 41. Minang JT, Troye-Blomberg M, Lundeberg L, et al. Nickel elicits
15-year experience. J Am Acad Dermatol 2016;75:410–9.e3. concomitant and correlated in vitro production of Th1-, Th2-type and